​

Intellia Therapeutics (NTLA) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NTLA Stock Forecast

Intellia Therapeutics (NTLA) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $22.88, with a high of $48.00 and a low of $14.00. This represents a 54.70% increase from the last price of $14.79.

$10 $18 $26 $34 $42 $50 High: $48 Avg: $22.88 Low: $14 Last Closed Price: $14.79

NTLA Stock Rating

Intellia Therapeutics stock's rating consensus is Buy, based on 36 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 30 Buy (83.33%), 6 Hold (16.67%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 36 0 6 30 Strong Sell Sell Hold Buy Strong Buy

NTLA Price Target Upside V Benchmarks

TypeNameUpside
StockIntellia Therapeutics54.70%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts8912
Avg Price Target$25.25$24.00$25.92
Last Closing Price$14.79$14.79$14.79
Upside/Downside70.72%62.27%75.25%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2531651-25
Sep, 2531861-28
Aug, 2531961-29
Jul, 253186-128
Jun, 254186-129
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 28, 2025JMP Securities$29.00$14.7996.08%96.08%
Oct 28, 2025Bernstein$14.50$14.79-1.96%-1.96%
Oct 28, 2025Gena WangBarclays$24.00$14.7962.27%62.27%
Oct 28, 2025William PickeringTudor Pickering$14.50$14.79-1.96%-1.96%
Oct 28, 2025Luca IssiRBC Capital$14.00$14.79-5.34%-5.34%
Oct 27, 2025Chardan Capital$48.00$25.6087.50%224.54%
Oct 27, 2025Mitchell KapoorH.C. Wainwright$25.00$25.60-2.34%69.03%
Oct 06, 2025Silvan TuerkcanJMP Securities$33.00$19.9665.33%123.12%
Aug 13, 2025Debjit ChattopadhyayGuggenheim$14.00$11.2524.44%-5.34%
Feb 28, 2025Goldman Sachs$9.00$10.09-10.80%-39.15%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 28, 2025BarclaysOverweightOverweighthold
Oct 28, 2025CitigroupMarket OutperformMarket Outperformhold
Oct 28, 2025BernsteinMarket Performdowngrade
Oct 28, 2025RBC CapitalOutperformSector Performdowngrade
Oct 27, 2025William BlairOutperformMarket Performdowngrade
Oct 27, 2025GuggenheimBuyNeutraldowngrade
Oct 27, 2025H.C. WainwrightBuyBuyhold
Oct 27, 2025Bank of America SecuritiesBuyBuyhold
Oct 06, 2025CitigroupUnderperformOutperformupgrade
Sep 19, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-25 $-14 $-3 $8 $19 $30 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.24$-3.66$-6.37$-5.42$-5.25----
Avg Forecast$-2.28$-3.60$-6.16$-5.44$-5.31$-5.13$-4.98$-2.60$1.51
High Forecast$-0.55$-0.87$0.85$-4.98$-4.87$-4.04$-3.14$27.79$5.39
Low Forecast$-5.30$-8.38$-21.52$-5.71$-5.63$-6.57$-7.02$-9.26$-0.20
Surprise %-1.75%1.67%3.41%-0.37%-1.13%----

Revenue Forecast

$0 $800M $2B $2B $3B $4B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$57.99M$33.05M$52.12M$36.27M-----
Avg Forecast$66.73M$29.16M$51.90M$50.66M$53.93M$53.11M$39.23M$452.34M$1.25B
High Forecast$134.73M$58.87M$151.42M$79.15M$63.58M$158.30M$116.94M$452.71M$3.71B
Low Forecast$27.73M$12.12M$6.49M$37.80M$45.78M$6.78M$5.01M$451.97M$159.15M
Surprise %-13.09%13.36%0.43%-28.39%-----

Net Income Forecast

$-1B $-300M $400M $1B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-125.57M$-259.72M$-490.21M$-481.19M$-519.02M----
Avg Forecast$-123.01M$-230.77M$-354.34M$-481.19M$-466.19M$-527.95M$-559.65M$-271.07M$133.85M
High Forecast$-98.41M$-184.61M$-283.48M$-384.95M$-432.25M$-358.27M$-278.87M$2.47B$478.51M
Low Forecast$-147.61M$-276.92M$-425.21M$-577.43M$-500.12M$-583.20M$-622.89M$-821.94M$-17.93M
Surprise %2.08%12.55%38.34%-11.33%----

NTLA Forecast FAQ

Is Intellia Therapeutics stock a buy?

Intellia Therapeutics stock has a consensus rating of Buy, based on 36 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 30 Buy, 6 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Intellia Therapeutics is a favorable investment for most analysts.

What is Intellia Therapeutics's price target?

Intellia Therapeutics's price target, set by 36 Wall Street analysts, averages $22.88 over the next 12 months. The price target range spans from $14 at the low end to $48 at the high end, suggesting a potential 54.70% change from the previous closing price of $14.79.

How does Intellia Therapeutics stock forecast compare to its benchmarks?

Intellia Therapeutics's stock forecast shows a 54.70% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Intellia Therapeutics over the past three months?

  • October 2025: 12.00% Strong Buy, 64.00% Buy, 20.00% Hold, 4.00% Sell, 0% Strong Sell.
  • September 2025: 10.71% Strong Buy, 64.29% Buy, 21.43% Hold, 3.57% Sell, 0% Strong Sell.
  • August 2025: 10.34% Strong Buy, 65.52% Buy, 20.69% Hold, 3.45% Sell, 0% Strong Sell.

What is Intellia Therapeutics’s EPS forecast?

Intellia Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-5.13, marking a -2.29% decrease from the reported $-5.25 in 2024. Estimates for the following years are $-4.98 in 2026, $-2.6 in 2027, and $1.51 in 2028.

What is Intellia Therapeutics’s revenue forecast?

Intellia Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $53.11M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $39.23M, followed by $452.34M for 2027, and $1.25B for 2028.

What is Intellia Therapeutics’s net income forecast?

Intellia Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-528M, representing an 1.72% increase from the reported $-519M in 2024. Projections indicate $-560M in 2026, $-271M in 2027, and $133.85M in 2028.